| Title | Novel multiple tyrosine kinase inhibitor ponatinib inhibits bFGF-activated signaling in neuroblastoma cells and suppresses neuroblastoma growth in vivo |
| Authors | Li, Haoyu Wang, Yongfeng Chen, Zhenghu Lu, Jiaxiong Pan, Jessie Yu, Yang Zhao, Yanling Zhang, Huiyuan Hu, Ting Liu, Qing Yang, Jianhua |
| Affiliation | Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Hunan, Peoples R China. Inst Skull Base Surg & Neurooncol Hunan Prov, Changsha 410008, Hunan, Peoples R China. Peking Univ, Hlth Sci Ctr, Dept Microbiol, Beijing 100191, Peoples R China. Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Pediat, Texas Childrens Canc Ctr, Houston, TX 77030 USA. Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Ophthalmol, Shanghai 200072, Peoples R China. Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Hunan, Peoples R China. Liu, Q (reprint author), Inst Skull Base Surg & Neurooncol Hunan Prov, Changsha 410008, Hunan, Peoples R China. Yang, JH (reprint author), Baylor Coll Med, Dan L Duncan Canc Ctr, Dept Pediat, Texas Childrens Canc Ctr, Houston, TX 77030 USA. |
| Keywords | neuroblastoma ponatinib FGFR1 apoptosis chemoresistance SMALL-MOLECULE INHIBITORS CHROMOSOME-POSITIVE LEUKEMIAS CHRONIC MYELOID-LEUKEMIA CANCER-THERAPY LUNG-CANCER HEMATOLOGIC MALIGNANCIES CRIZOTINIB RESISTANCE MONOCLONAL-ANTIBODIES PI3K/AKT/MTOR PATHWAY FGFR1 ABNORMALITIES |
| Issue Date | 2017 |
| Publisher | ONCOTARGET |
| Citation | ONCOTARGET.2017,8(4),5874-5884. |
| Abstract | Neuroblastoma (NB) is one of the most common pediatric malignancies in children. Abnormal activation of receptor tyrosine kinases contributes to the pathological development of NB. Therefore, targeting tyrosine kinase receptors to cure NB is a promising strategy. Here, we report that a multi-targeted tyrosine kinase inhibitor ponatinib inhibited NB cell proliferation and induced NB cell apoptosis in a dose-dependent manner. In addition, ponatinib suppressed the colony formation ability of NB cells. Mechanistically, ponatinib effectively inhibited the FGFR1-activated signaling pathway. Ponatinib also enhanced the cytotoxic effects of doxorubicin on NB cells. Furthermore, ponatinib demonstrated anti-tumor efficacy in vivo by inhibiting tumor growth in an orthotopic xenograft NB mouse model. In summary, our results showed that ponatinib inhibited NB growth both in vitro and in vivo. |
| URI | http://hdl.handle.net/20.500.11897/493075 |
| ISSN | 1949-2553 |
| DOI | 10.18632/oncotarget.11580 |
| Indexed | SCI(E) PubMed |
| Appears in Collections: | 医学部待认领 |
